Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue characterized by spontaneous fractures, bone deformities, impaired growth and posture, as well as extra-skeletal manifestations. Recent studies have underlined an impairment of the osteotendinous complex in mice models of OI. The first objective of the present work was to further investigate the properties of tendons in the osteogenesis imperfecta mouse (oim), a model characterized by a mutation in the COL1A2 gene. The second objective was to identify the possible beneficial effects of zoledronic acid on tendons. Oim received a single intravenous injection of zoledronic acid (ZA group) at 5 weeks and were euthanized at 14 weeks. Their tendons were compared with those of...
Osteogenesis imperfecta (OI) is a heritable disorder of connective tissue associated with fractures,...
Introduction: The Brittle IV (Brtl) mouse was developed as a knock-in model for osteogenesis imperfe...
Aref, M. W., McNerny, E. M. B., Brown, D., Jepsen, K. J., & Allen, M. R. (2016). Zoledronate treatme...
Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue characterized by spontaneous...
Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue characterized by low bone ma...
In this study, we examined the therapeutic potential of anti-Sclerostin Antibody (Scl-Ab) and bispho...
Background and purpose: Outcome after ligament reconstruction or tendon repair depends on secure ten...
<p>(A) Femur Bone Mineral Density (BMD). (B) Trabecular bone volume on tissue volume (BV/TV) of the ...
We compared the effects of a nitrogen-containing bisphosphonate (N-BP), zoledronic acid (ZA), and an...
Osteogenesis Imperfecta (OI) is a dominant negative disorder of connective tissue. OI patients prese...
<p>(A–C) Histomorphometry parameter and images perform on the femur. (A) Number of Osteoclast on Bon...
<p>Osteocyte number and empty lacunae in the jaw (A) and the mid-shaft femur (B), (C–D) Toluidine bl...
Osteogenesis imperfecta is a rare genetic disorder characterized by bone fragility, due to alteratio...
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic a...
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic a...
Osteogenesis imperfecta (OI) is a heritable disorder of connective tissue associated with fractures,...
Introduction: The Brittle IV (Brtl) mouse was developed as a knock-in model for osteogenesis imperfe...
Aref, M. W., McNerny, E. M. B., Brown, D., Jepsen, K. J., & Allen, M. R. (2016). Zoledronate treatme...
Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue characterized by spontaneous...
Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue characterized by low bone ma...
In this study, we examined the therapeutic potential of anti-Sclerostin Antibody (Scl-Ab) and bispho...
Background and purpose: Outcome after ligament reconstruction or tendon repair depends on secure ten...
<p>(A) Femur Bone Mineral Density (BMD). (B) Trabecular bone volume on tissue volume (BV/TV) of the ...
We compared the effects of a nitrogen-containing bisphosphonate (N-BP), zoledronic acid (ZA), and an...
Osteogenesis Imperfecta (OI) is a dominant negative disorder of connective tissue. OI patients prese...
<p>(A–C) Histomorphometry parameter and images perform on the femur. (A) Number of Osteoclast on Bon...
<p>Osteocyte number and empty lacunae in the jaw (A) and the mid-shaft femur (B), (C–D) Toluidine bl...
Osteogenesis imperfecta is a rare genetic disorder characterized by bone fragility, due to alteratio...
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic a...
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic a...
Osteogenesis imperfecta (OI) is a heritable disorder of connective tissue associated with fractures,...
Introduction: The Brittle IV (Brtl) mouse was developed as a knock-in model for osteogenesis imperfe...
Aref, M. W., McNerny, E. M. B., Brown, D., Jepsen, K. J., & Allen, M. R. (2016). Zoledronate treatme...